Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
New research from 23and ME sheds a light on why GLP-1 weight-loss drugs work differently across patients, with two studies suggesting that genetic variation and cardiovascular mechanisms independent of weight loss may both play significant roles in determining individual outcomes
WO-2025161997-A1
A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer
Similarities between acylcarnitine profiles in large for gestational age newborns and obesity
.png)
US$ 21.39
US$ 28.83
US$ 27.06
US$ 27.00
